Systemic inflammatory mediators (indirect modulation via paracrine mechanisms)

Systemic inflammatory mediators – indirect modulation via paracrine mechanisms refers to a therapeutic strategy where the systemic immune response is regulated through the secretion of bioactive factors by intermediary cells or agents. Rather than directly neutralizing a specific cytokine like TNF-alpha, this strategy utilizes the "paracrine effect"—often via Mesenchymal Stem Cells (MSCs) or their extracellular vesicles—to release a broad spectrum of immunomodulatory molecules such as IL-10, TGF-beta, and prostaglandin E2 (Galipeau & Sensébé, 2018). These secreted factors interact with local and circulating immune cells to suppress pro-inflammatory signaling and promote tissue repair (Harrell et al., 2019). This mechanism is particularly relevant in treating complex, multi-factorial conditions like sepsis, acute respiratory distress syndrome (ARDS), and cytokine release syndrome, where targeting a single mediator is often insufficient (Singer et al., 2016). By indirectly modulating the inflammatory environment, this approach aims to restore systemic homeostasis and prevent organ damage. Clinical development in this area focuses on cell-based therapies and "cell-free" secretome products that can orchestrate these complex paracrine interactions (Khoury et al., 2020).

Other names

Paracrine immunomodulationIndirect cytokine modulationMSC-mediated paracrine signalingBystander effect modulationSecretome-mediated systemic modulation

Indirect modulation of systemic inflammatory mediators via the paracrine secretion of immunomodulatory factors (e.g., IL-10, TGF-beta, PGE2) from therapeutic cells or vesicles, which subsequently alter the activation state of systemic immune cells such as macrophages and T-cells.